MarketCap
Facebook
X
TelegramCountry |
 Israel |
IPO year |
2014 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
27.2 M |
Market Cap[1] |
$ 329 M |
EBITDA (LTM) |
$ -42.7 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ALX Oncology Holdings
ALXO
|
$ 1.14 | -2.56 % | $ 61.2 M | Nasdaq Global Select Market,SPB |  USA |
 |
Heron Therapeutics
HRTX
|
$ 0.3 | -0.46 % | $ 50 M | Nasdaq Global Select Market,SPB | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.55 | 0.85 % | $ 286 M | Nasdaq Capital Market | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 17.02 | 0.98 % | $ 2.29 B | Nasdaq Global Market |  Canada |
 |
iBio
IBIO
|
$ 0.71 | -1.28 % | $ 73.9 M | NYSE American | USA |
 |
ImmuCell Corporation
ICCC
|
$ 10.21 | -0.37 % | $ 92.2 M | Nasdaq Global Select Market | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.51 | -5.03 % | $ 148 M | Nasdaq Capital Market | USA |
 |
Immunome
IMNM
|
$ 17.89 | -0.54 % | $ 1.56 B | Nasdaq Global Select Market | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.57 | 9.03 % | $ 6.54 M | Nasdaq Capital Market | Canada |
 |
Inovio Pharmaceuticals
INO
|
$ 0.88 | -1.82 % | $ 41.3 M | Nasdaq Global Select Market | USA |
 |
Innoviva
INVA
|
$ 21.06 | 1.91 % | $ 1.42 B | Nasdaq Global Select Market | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 13.78 | -2.24 % | $ 4.92 M | Nasdaq Global Market,SPB | USA |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 424.81 | 1.06 % | $ 33.2 B | Nasdaq Global Select Market,SPB | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | Nasdaq Global Market | USA |
 |
Keros Therapeutics
KROS
|
$ 11.35 | 0.62 % | $ 422 M | Nasdaq Global Select Market | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 20.39 | 5.79 % | $ 7.52 B | Nasdaq Global Select Market | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 308.16 | 1.53 % | $ 5.96 B | Nasdaq Global Select Market,SPB | USA |
 |
BridgeBio Pharma
BBIO
|
$ 68.11 | -0.65 % | $ 13 B | Nasdaq Global Select Market,SPB | USA |
 |
Annovis Bio
ANVS
|
$ 0.95 | -4.92 % | $ 19.5 M | NYSE American | USA |
 |
Liquidia Corporation
LQDA
|
$ 43.75 | 2.58 % | $ 3.77 B | Nasdaq Capital Market | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | Nasdaq Capital Market | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.46 | 2.81 % | $ 530 M | Nasdaq Global Select Market | USA |
 |
Mustang Bio
MBIO
|
$ 0.36 | -1.89 % | $ 1.77 M | Nasdaq Global Market | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.88 | 3.01 % | $ 1.65 B | Nasdaq Global Select Market | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 437.59 | 0.77 % | $ 9.82 B | Nasdaq Global Select Market,SPB | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | Nasdaq Global Select Market | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.69 | -10.37 % | $ 96.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 83.44 | 3.79 % | $ 4.19 B | Nasdaq Global Select Market | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.49 | -7.45 % | $ 470 K | Nasdaq Capital Market | USA |
 |
MannKind Corporation
MNKD
|
$ 3.23 | 1.25 % | $ 987 M | Nasdaq Global Market | USA |
|
Monopar Therapeutics
MNPR
|
$ 70.52 | -0.18 % | $ 523 M | Nasdaq Global Select Market | USA |
 |
Marker Therapeutics
MRKR
|
$ 0.9 | -6.16 % | $ 13.8 M | Nasdaq Global Market | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 7.5 | 3.69 % | $ 1.08 B | Nasdaq Global Select Market | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.66 | -2.92 % | $ 9.09 M | NYSE American | USA |
 |
Neurocrine Biosciences
NBIX
|
$ 145.91 | 2.25 % | $ 14.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | Nasdaq Capital Market | USA |
 |
Biogen
BIIB
|
$ 252.25 | 0.62 % | $ 37 B | Nasdaq Global Select Market,SPB | USA |
 |
Minerva Neurosciences
NERV
|
$ 2.2 | -4.35 % | $ 18.6 M | Nasdaq Global Market | USA |
 |
Nektar Therapeutics
NKTR
|
$ 37.17 | -0.12 % | $ 627 M | Nasdaq Global Select Market,SPB | USA |
 |
Nkarta
NKTX
|
$ 1.87 | 4.47 % | $ 138 M | Nasdaq Global Select Market | USA |
 |
NanoViricides
NNVC
|
$ 1.37 | -2.14 % | $ 27.7 M | NYSE American | USA |
 |
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | Nasdaq Global Market | USA |
 |
Nurix Therapeutics
NRIX
|
$ 25.55 | 0.83 % | $ 2.21 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.